United Therapeutics Corporation (NASDAQ:UTHR) Q4 2020 Earnings Conference Call February 24, 2021 9:00 AM ET
Company Participants
Dewey Steadman - Head, IR
Martine Rothblatt - Chairman and CEO
Michael Benkowitz - President and COO
Leigh Peterson - VP, Product Development
James Edgemond - CFO and Treasurer
Conference Call Participants
Joseph Thome - Cowen and Company
Liana Moussatos - Wedbush
Eun Yang - Jefferies
Jessica Fye - JPMorgan
Martin Auster - Credit Suisse
Hartaj Singh - Oppenheimer
Terence Flynn - Goldman Sachs
Operator
Good morning, and welcome to the United Therapeutics Corporation, Fourth Quarter 2020 Earnings Call. My name is Kenzie, and I will be your conference operator today. [Operator Instructions]
I will now turn the conference call over to Mr. Dewey Steadman, Head of Investor Relations at United Therapeutics.
Dewey Steadman
Good morning. It's my pleasure to welcome you to the United Therapeutics Corporation fourth quarter 2020 earnings call. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowitz, our President and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer and Treasurer; and Dr. Leigh Peterson, Vice President of Product Development.
Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Form 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update these forward-looking statements.
Today's remarks may also include financial measures that were not prepared in accordance with U.S. Generally Accepted Accounting Principles. Reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures can be found at our earnings release available on our website at www.unither.com.
Today's remarks may discuss the progress and results of clinical
- Read more current UTHR analysis and news
- View all earnings call transcripts